Related Experiment Video
Updated: Jul 24, 2025

Characterization of the Effects of Migrastatic Inhibitors on 3D Tumor Spheroid Invasion by High-resolution Confocal Microscopy
Published on: September 16, 2019
The HDAC2-MTA3 interaction induces nonsmall cell lung cancer cell migration and invasion by targeting c-Myc and
Bin Wang1, Xiao-Yong Shen1, Lin-Yue Pan2
1Shanghai Key Laboratory of Clinical Geriatric Medicine, Department of Thoracic Surgery, The Affiliated Huadong Hospital of Fudan University, Shanghai, China.
Abstract:
Genome-wide association studies have identified numerous single-nucleotide polymorphisms (SNPs) associated with lung cancer; however, the functions of histone deacetylase 2 (HDAC2) rs13213007 and HDAC2 in nonsmall cell lung cancer (NSCLC) remain unclear. Here we identified HDAC2 rs13213007 as a risk SNP and showed that HDAC2 was upregulated in both peripheral blood mononuclear cells (PBMCs) and NSCLC tissues with the rs13213007 A/A genotype compared with those with the rs13213007 G/G or G/A genotype. Patient clinical data indicated strong associations between rs13213007 genotype and N classification. Immunohistochemical staining confirmed that higher expression of HDAC2 was associated with NSCLC progression. Furthermore, we generated 293T cells with the rs13213007 A/A genotype using CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing. Chromatin immunoprecipitation sequencing followed by motif analysis showed that HDAC2 can bind to c-Myc in rs13213007 A/A 293T cells. Cell Counting Kit-8, colony formation, wound-healing, and Transwell assays revealed that HDAC2 upregulates c-Myc and cyclin D1 expression and promotes NSCLC cell proliferation, migration, and invasion. Co-immunoprecipitation, quantitative reverse transcription-polymerase chain reaction, and western blot analysis assays showed that MTA3 interacts with HDAC2, decreases HDAC2 expression, and rescues the migration and invasion abilities of NSCLC cells. Taken together, these findings identify HDAC2 as a potential therapeutic biomarker in NSCLC.
Insights
This study identifies the histone deacetylase 2 (HDAC2) rs13213007 single-nucleotide polymorphism (SNP) as a risk factor for nonsmall cell lung cancer (NSCLC). Upregulated HDAC2 promotes NSCLC progression by enhancing cell proliferation, migration, and invasion.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Genome-wide association studies have linked numerous single-nucleotide polymorphisms (SNPs) to lung cancer.
- The specific roles of histone deacetylase 2 (HDAC2) and its SNP rs13213007 in nonsmall cell lung cancer (NSCLC) require further elucidation.
Purpose of the Study:
- To investigate the functional significance of the HDAC2 rs13213007 SNP in NSCLC.
- To determine the association between HDAC2 expression, its rs13213007 genotype, and NSCLC progression.
- To explore the molecular mechanisms by which HDAC2 influences NSCLC cell behavior.
Main Methods:
- Genotyping and analysis of HDAC2 rs13213007 in NSCLC patients.
- Immunohistochemical staining to assess HDAC2 expression in tumor tissues.
- CRISPR/Cas9 gene editing to create cells with specific genotypes.
- Chromatin immunoprecipitation sequencing (ChIP-seq) and motif analysis.
- Cell proliferation, migration, and invasion assays (Cell Counting Kit-8, colony formation, wound-healing, Transwell).
- Co-immunoprecipitation, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and Western blot analysis.
Main Results:
- HDAC2 rs13213007 was identified as a risk SNP for NSCLC.
- HDAC2 was upregulated in peripheral blood mononuclear cells (PBMCs) and NSCLC tissues with the rs13213007 A/A genotype.
- HDAC2 expression correlated with N classification and NSCLC progression.
- HDAC2 binds to c-Myc in rs13213007 A/A cells, upregulating c-Myc and cyclin D1.
- HDAC2 promotes NSCLC cell proliferation, migration, and invasion.
- MTA3 interacts with HDAC2, reducing its expression and rescuing cell migration and invasion.
Conclusions:
- HDAC2 rs13213007 is a risk SNP associated with NSCLC progression.
- Upregulated HDAC2, particularly with the A/A genotype, drives NSCLC cell proliferation, migration, and invasion via c-Myc and cyclin D1.
- MTA3 acts as a negative regulator of HDAC2 in NSCLC.
- HDAC2 represents a potential therapeutic biomarker for NSCLC.
Related Concept Videos
Induced Pluripotent Stem Cells
Somatic...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
lncRNA - Long Non-coding RNAs
Cancer Cell Migration through Invadopodia
MAPK Signaling Cascades

